Tomasz Sablinksi, Founder, CEO, Transparency Life Sciences
Lorenzo Albanello, Open medical data to improve personalized medicine
Marty Tenenbaum, Cancer Commons
Lindy Avey, Curious
Collection of in-depth patient phenotypic data in basic and clinical research presents significant challenges and may partly be one of the gating factors in advancing the field of personalized healthcare. Using the web and social networking tools, a new research paradigm is emerging that incorporates higher levels of patient involvement (Research 2.0) enabling prospective, dynamic engagement with the ‘experts’. How will drug development, testing, and approval as well as comparative medicine be able to embrace this shift in protocol design for a more progressive approach?
Marissa Nelson, 23andMe
Nicole Boice, RARE Project, Global Genes Project, crowd-funding of rare diseases
The Open Science Summit unites researchers, life science industry professionals, students, patients and other stakeholders to discuss the future of collaborative science and innovation.
This, the second year, features in-depth sessions on new models for drug discovery and clinical trials, personal genomics, the patent system, the future of scientific publications, and more.
Lorenzo Albanello is a synthetic biologist who studies therapies for human rejuvenation. Previously he was a developer of knowledge bases in bioinformatics for an Italian corporation with the aim of translating human scientific knowledge into shared formats that can enable artificial intelligence.
He is also interested in bio-hacking and DIY scientific hardware. In all his experiences he realized how the scientific research rate and quality will be dramatically boosted by greater openness, and this led him to actively join the Open Science movement.
Linda Avey is co-founder and CEO of Curious, Inc., a personal data discovery platform. Previously, she co-founded 23andMe, the leading personal genetics company.
As Founder of the Children's Rare Disease Network and the Global Genes Project, Nicole has embarked on the journey to help families affected by rare disease based on her personal experience with a family friend, their struggles and challenges over the course of 2 1/2 years while working to find a diagnosis for their son. Realizing these families need an outside champion for all rare disease, she believes that 'power in numbers' apply to this effort, and works to create collaborations within the entire rare disease community and build greater public awareness for rare disease, which affects over 30 million within the US.
In business, Nicole has held numerous consulting, sales and marketing executive roles in her 20 years in business. Nicole has a passion for launching new products, building new organizations and "making the impossible possible". Nicole has worked with world-class organizations within Life Sciences Media as a founding member and Associate Publisher of The Journal of Life Sciences, has also worked in the Life Sciences Venture Capital Community in media, and in the Pharmaceutical and High Tech Sectors. Organizations include Zoomedia, Burrill & Company, Schering Plough, Imagine Media & CMP Media.
A Graduate of the University of California San Diego, with a BA in Political Science and formerly enrolled in the masters program at Pepperdine University. Nicole currently resides in Southern California with her husband and two children, enjoying her role as business woman, mother, wife, coach and outdoor enthusiast.
Marisa Nelson is the Business Development Manager at 23andMe. She communicates the company's vision and unique strengths to generate revenue and create strategic alliances; Assists in identifying, negotiating and maintaining revenue generating business partnerships; Creates and implement participant recruitment plans for various 23andMe research communities. Two initiatives have launched under her leadership: the 23andMe Sarcoma Community and Roots into the Future, an African American research initiative; Initiated a genetics education program for university level students and professors.
Tomasz Sablinski Ph.D.
Dr. Tomasz Sablinski is the Head of Clinical Development and a member of the Executive Committee of Celtic Therapeutics Development (CTD). Dr. Sablinski joined CTD with twenty eight years of experience in healthcare, including his last fifteen years in the global pharmaceutical industry. His career includes ten years of clinical practice as a surgeon specializing in renal transplantation and general surgery, and several years of basic research in immunobiology.
Prior to joining CTD, Dr. Sablinski served as Vice President at Novartis Pharmaceuticals Corp. in charge of US Clinical Development and Medical Affairs. Prior to this, Dr. Sablinski held several leadership positions at Novartis headquarters including Vice President of Clinical Research and Development and Head of Global-Japanese Coordination. He also held multiple leadership positions in Novartis' Transplantation Business Unit. He participated in, and supervised numerous NDA and IND submissions in the US, Europe and Japan. Dr. Sablinski earned his MD and his Ph.D. in transplant immunology at Warsaw Medical School and his bachelor degrees at Copernicus College in Warsaw, Poland.
Dr. Marty Tenenbaum
Marty Tenenbaum is the Chairman of CollabRx, a provider of Web-based applications and services that help cancer patients and their physicians selectoptimal treatments and trials. Dr. Tenenbaum is also the founder of CancerCommons, an open science community that compiles and continually refinesinformation about cancer subtypes and treatments, based on the literature andactual patient outcomes.
Dr. Tenenbaum was educated at MIT and Stanford in the 1960s. He spent the 1970s doing artificial intelligence research at SRI, the 1980s managing computer science research for Schlumberger, and the 1990s pioneering Internet commerce. He is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Patients Like Me, the Public Library of Science, Efficient Finance, and Earth Analytics Group.